In vitro correction of cystic fibrosis epithelial cell lines by small fragment homologous replacement (SFHR) technique

Federica Sangiuolo, Emanuela Bruscia, Annalucia Serafino, Anna Maria Nardone, Emanuela Bonifazi, Monica Lais, Dieter C. Gruenert, Giuseppe Novelli

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

Background: SFHR (small fragment homologous replacement)-mediated targeting is a process that has been used to correct specific mutations in mammalian cells. This process involves both chemical and cellular factors that are not yet defined. To evaluate potential of this technique for gene therapy it is necessary to characterize gene transfer efficacy in terms of the transfection vehicle, the genetic target, and the cellular processing of the DNA and DNA-vehicle complex. Methods: In this study, small fragments of genomic cystic fibrosis (CF) transmembrane conductance regulator (CFTR) DNA, that comprise the wild-type and ΔF508 sequences, were transfected into immortalized CF and normal airway epithelial cells, respectively. Homologous replacement was evaluated using PCR and sequence-based analyses of cellular DNA and RNA. Individual stages of cationic lipid-facilitated SFHR in cultured cell lines were also examined using transmission electron microscopy (TEM). Results: We demonstrated that the lipid/DNA (+/-) ratio influences the mode of entry into the cell and therefore affects the efficacy of SFHR-mediated gene targeting. Lipid/DNA complexes with more negative ratios entered the cell via a plasma membrane fusion pathway. Transfer of the DNA that relies on an endocytic pathway appeared more effective at mediating SFHR. In addition, it was also clear that there is a correlation between the specific cell line transfected and the optimal lipid/DNA ratio. Conclusions: These studies provide new insights into factors that underlie SFHR-mediated gene targeting efficacy and into the parameters that can be modulated for its optimization.

Original languageEnglish
Article number8
JournalBMC Medical Genetics
Volume3
DOIs
Publication statusPublished - Sep 23 2002

Fingerprint

Cystic Fibrosis
Epithelial Cells
Cell Line
DNA
Lipids
Gene Targeting
Cystic Fibrosis Transmembrane Conductance Regulator
Membrane Fusion
In Vitro Techniques
Transmission Electron Microscopy
Genetic Therapy
Transfection
Sequence Analysis
Cultured Cells
Cell Membrane
RNA
Polymerase Chain Reaction
Mutation
Genes

Keywords

  • Cystic fibrosis transmembrane conductance regulator (CFTR)
  • Gene targeting
  • Gene therapy
  • Transfection
  • Transmission electron microscopy (TEM)

ASJC Scopus subject areas

  • Medicine(all)
  • Genetics(clinical)

Cite this

Sangiuolo, F., Bruscia, E., Serafino, A., Nardone, A. M., Bonifazi, E., Lais, M., ... Novelli, G. (2002). In vitro correction of cystic fibrosis epithelial cell lines by small fragment homologous replacement (SFHR) technique. BMC Medical Genetics, 3, [8]. https://doi.org/10.1186/1471-2350-3-8

In vitro correction of cystic fibrosis epithelial cell lines by small fragment homologous replacement (SFHR) technique. / Sangiuolo, Federica; Bruscia, Emanuela; Serafino, Annalucia; Nardone, Anna Maria; Bonifazi, Emanuela; Lais, Monica; Gruenert, Dieter C.; Novelli, Giuseppe.

In: BMC Medical Genetics, Vol. 3, 8, 23.09.2002.

Research output: Contribution to journalArticle

Sangiuolo, F, Bruscia, E, Serafino, A, Nardone, AM, Bonifazi, E, Lais, M, Gruenert, DC & Novelli, G 2002, 'In vitro correction of cystic fibrosis epithelial cell lines by small fragment homologous replacement (SFHR) technique', BMC Medical Genetics, vol. 3, 8. https://doi.org/10.1186/1471-2350-3-8
Sangiuolo, Federica ; Bruscia, Emanuela ; Serafino, Annalucia ; Nardone, Anna Maria ; Bonifazi, Emanuela ; Lais, Monica ; Gruenert, Dieter C. ; Novelli, Giuseppe. / In vitro correction of cystic fibrosis epithelial cell lines by small fragment homologous replacement (SFHR) technique. In: BMC Medical Genetics. 2002 ; Vol. 3.
@article{2add0cca374a4f5cb3ae1daf62815c15,
title = "In vitro correction of cystic fibrosis epithelial cell lines by small fragment homologous replacement (SFHR) technique",
abstract = "Background: SFHR (small fragment homologous replacement)-mediated targeting is a process that has been used to correct specific mutations in mammalian cells. This process involves both chemical and cellular factors that are not yet defined. To evaluate potential of this technique for gene therapy it is necessary to characterize gene transfer efficacy in terms of the transfection vehicle, the genetic target, and the cellular processing of the DNA and DNA-vehicle complex. Methods: In this study, small fragments of genomic cystic fibrosis (CF) transmembrane conductance regulator (CFTR) DNA, that comprise the wild-type and ΔF508 sequences, were transfected into immortalized CF and normal airway epithelial cells, respectively. Homologous replacement was evaluated using PCR and sequence-based analyses of cellular DNA and RNA. Individual stages of cationic lipid-facilitated SFHR in cultured cell lines were also examined using transmission electron microscopy (TEM). Results: We demonstrated that the lipid/DNA (+/-) ratio influences the mode of entry into the cell and therefore affects the efficacy of SFHR-mediated gene targeting. Lipid/DNA complexes with more negative ratios entered the cell via a plasma membrane fusion pathway. Transfer of the DNA that relies on an endocytic pathway appeared more effective at mediating SFHR. In addition, it was also clear that there is a correlation between the specific cell line transfected and the optimal lipid/DNA ratio. Conclusions: These studies provide new insights into factors that underlie SFHR-mediated gene targeting efficacy and into the parameters that can be modulated for its optimization.",
keywords = "Cystic fibrosis transmembrane conductance regulator (CFTR), Gene targeting, Gene therapy, Transfection, Transmission electron microscopy (TEM)",
author = "Federica Sangiuolo and Emanuela Bruscia and Annalucia Serafino and Nardone, {Anna Maria} and Emanuela Bonifazi and Monica Lais and Gruenert, {Dieter C.} and Giuseppe Novelli",
year = "2002",
month = "9",
day = "23",
doi = "10.1186/1471-2350-3-8",
language = "English",
volume = "3",
journal = "BMC Medical Genetics",
issn = "1471-2350",
publisher = "BioMed Central",

}

TY - JOUR

T1 - In vitro correction of cystic fibrosis epithelial cell lines by small fragment homologous replacement (SFHR) technique

AU - Sangiuolo, Federica

AU - Bruscia, Emanuela

AU - Serafino, Annalucia

AU - Nardone, Anna Maria

AU - Bonifazi, Emanuela

AU - Lais, Monica

AU - Gruenert, Dieter C.

AU - Novelli, Giuseppe

PY - 2002/9/23

Y1 - 2002/9/23

N2 - Background: SFHR (small fragment homologous replacement)-mediated targeting is a process that has been used to correct specific mutations in mammalian cells. This process involves both chemical and cellular factors that are not yet defined. To evaluate potential of this technique for gene therapy it is necessary to characterize gene transfer efficacy in terms of the transfection vehicle, the genetic target, and the cellular processing of the DNA and DNA-vehicle complex. Methods: In this study, small fragments of genomic cystic fibrosis (CF) transmembrane conductance regulator (CFTR) DNA, that comprise the wild-type and ΔF508 sequences, were transfected into immortalized CF and normal airway epithelial cells, respectively. Homologous replacement was evaluated using PCR and sequence-based analyses of cellular DNA and RNA. Individual stages of cationic lipid-facilitated SFHR in cultured cell lines were also examined using transmission electron microscopy (TEM). Results: We demonstrated that the lipid/DNA (+/-) ratio influences the mode of entry into the cell and therefore affects the efficacy of SFHR-mediated gene targeting. Lipid/DNA complexes with more negative ratios entered the cell via a plasma membrane fusion pathway. Transfer of the DNA that relies on an endocytic pathway appeared more effective at mediating SFHR. In addition, it was also clear that there is a correlation between the specific cell line transfected and the optimal lipid/DNA ratio. Conclusions: These studies provide new insights into factors that underlie SFHR-mediated gene targeting efficacy and into the parameters that can be modulated for its optimization.

AB - Background: SFHR (small fragment homologous replacement)-mediated targeting is a process that has been used to correct specific mutations in mammalian cells. This process involves both chemical and cellular factors that are not yet defined. To evaluate potential of this technique for gene therapy it is necessary to characterize gene transfer efficacy in terms of the transfection vehicle, the genetic target, and the cellular processing of the DNA and DNA-vehicle complex. Methods: In this study, small fragments of genomic cystic fibrosis (CF) transmembrane conductance regulator (CFTR) DNA, that comprise the wild-type and ΔF508 sequences, were transfected into immortalized CF and normal airway epithelial cells, respectively. Homologous replacement was evaluated using PCR and sequence-based analyses of cellular DNA and RNA. Individual stages of cationic lipid-facilitated SFHR in cultured cell lines were also examined using transmission electron microscopy (TEM). Results: We demonstrated that the lipid/DNA (+/-) ratio influences the mode of entry into the cell and therefore affects the efficacy of SFHR-mediated gene targeting. Lipid/DNA complexes with more negative ratios entered the cell via a plasma membrane fusion pathway. Transfer of the DNA that relies on an endocytic pathway appeared more effective at mediating SFHR. In addition, it was also clear that there is a correlation between the specific cell line transfected and the optimal lipid/DNA ratio. Conclusions: These studies provide new insights into factors that underlie SFHR-mediated gene targeting efficacy and into the parameters that can be modulated for its optimization.

KW - Cystic fibrosis transmembrane conductance regulator (CFTR)

KW - Gene targeting

KW - Gene therapy

KW - Transfection

KW - Transmission electron microscopy (TEM)

UR - http://www.scopus.com/inward/record.url?scp=0042368424&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0042368424&partnerID=8YFLogxK

U2 - 10.1186/1471-2350-3-8

DO - 10.1186/1471-2350-3-8

M3 - Article

VL - 3

JO - BMC Medical Genetics

JF - BMC Medical Genetics

SN - 1471-2350

M1 - 8

ER -